NEW YORK (GenomeWeb News) – Credit Suisse on Monday initiated coverage of Genomic Health with an Outperform rating, Myriad Genetics with a Neutral rating, and Sequenom with an Underperform rating.

Analyst Vamil Divan initiated coverage of Genomic Health with a $43 price target and in a research note highlighted the firm's portfolio of Oncotype tests. He called Oncotype Dx Breast "a best-in-class asset that is likely to gain traction in other forms of breast cancer," and added that Oncotype Dx Colon is gaining positive reaction, driving uptake of the test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more